The “cancer immunogram”
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Visualizing the state of cancer–immune system interactions may spur personalized therapy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“markers of response to cancer therapy have continued to evolve and now include factors well beyond established tumor-centric markers”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Blank et al., 2016
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cited by
Items 701–748 of 748
Technological Advancements in Cancer Diagnosis and Prognosis
Reddy, P., Singh, P., Kuril, S. R., Priyadarshini, A., Gosipatala, S. B., Chand, G., Venkatesh Kumar, R., Kaur, T., Thakur, M., & Sobti, R. C. (2023) · Springer eBooks · doi:10.1007/978-981-99-2196-6_81-1
Stellenwert der Checkpoint Therapie bei viszeral-onkologischen Erkrankungen
Schlößer, H., & Schmidt, T. (2023) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2148-1979
Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer
Jarroudi, O. A., Bairi, K. E., Curigliano, G., & Afqir, S. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_2 · Cited by 1
Araújo, D. V., Fares, A. F., Silva, M. J. B. E., Pacheco, R. L., & Riera, R. (2024) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/9wvt7
Nanomedicines in Treatment of Cancer
Akhtar, B., Tanveer, A., Sharif, A., Anjum, F., Shahid, M., & Zia, S. (2023) · Learning materials in biosciences · doi:10.1007/978-981-99-7626-3_6
¿Cuál es la relación entre el cáncer de pene y el microbioma? Una revisión exploratoria
García‐Perdomo, H. A., Granados-Duque, V., & Spiess, P. E. (2024) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2024.01.012
A Review of Immunotherapy in the Treatment of Tumors
刘, 家. (2024) · Immunology Studies · doi:10.12677/is.2024.61001
ter Maat, L. S., van Duin, I. A. J., Verheijden, R. J., Moeskops, P., Verhoeff, J. J. C., Elias, S. G., van Amsterdam, W. A. C., Burgers, F. H., van den Berkmortel, F. W. P. J., Boers‐Sonderen, M. J., et al. (2024) · medRxiv · doi:10.1101/2024.03.01.24303607
CTLA-4 Inhibitors for the Treatment of Lung Cancer
Bhatt, S., Sharma, S., Patil, S., & Pujari, R. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_6
A multidimensional analysis of MRPL17 protein in human tumorsPreprint
Li, H., Xie, X., Zhang, L., & Fei, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4095111/v1
Technological Advancements in Cancer Diagnosis and Prognosis
Reddy, P., Singh, P., Kuril, S. R., Priyadarshini, A., Gosipatala, S. B., Chand, G., Venkatesh Kumar, R., Kaur, T., Thakur, M., & Sobti, R. C. (2024) · Springer eBooks · doi:10.1007/978-981-99-6263-1_81
Azees, S. A., Manoharan, R., Navaneeth, A. G., Leon, B. S., & Subramani, K. (2024) · Polycyclic aromatic compounds · doi:10.1080/10406638.2024.2399536
Lee, C., Wu, Y., Liao, T.-C., Hsiao, S.-H., Hsu, J. B., & Chang, T. (2024) · Cancers · doi:10.3390/cancers16183207
Artificial intelligence and the interplay between cancer and immunity
Gupta, R., Kurç, T., & Saltz, J. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95359-7.00015-7
Recent Advances and Opportunities in Cancer Cell Targeting by Surface Decoration: A Review
Shirsath, N. R., Jadhav, H., Jagtap, V. A., & Goswami, A. K. (2025) · Drug Metabolism and Bioanalysis Letters · doi:10.2174/0118723128365466250214093327 · Cited by 1
Glucocorticoids unleash immune-dependent melanoma control through inhibition of the GARP/TGF-β axisPreprint
Earnshaw, C. H., Dunn, P., Chiang, S., Moeini, A., Koufaki, M. A., Bonavita, E., Russo, M., Nebot-Bral, L., Hockenhull, K., Richardson, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.24.666619
Immunologische Grundlagen der Immunonkologie
Wölfel, T. (2025) · Die Onkologie · doi:10.1007/s00761-025-01791-4
Loss of ribosomal protein uL14 enables tumor escape from T cell immunosurveillance
Dopler, A., Kyei-Baffour, E. S., Kerkhoff, M. A. T., Alkan, F., Malka, Y., Hoefakker, K., van der Kammen, R., Hoekman, L., Bleijerveld, O. B., Bradarić, A., et al. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf024
Liu, J., Lingpiao, Z., Jiayin, H., Qiyun, H., & Yirong, Y. (2025) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2025.2567347
An Immune-Related Gene Signature for Determining Tumor Prognosis Based on Machine Learning
Yazdanpanah, F., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_310
Immune Checkpoint Inhibitors and Anti-angiogenic Therapy for Cancer
Solimando, A. G., & Ribatti, D. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_163
T-Cell Based Therapies: Clinical Applications and Challenges
Figueroa, I., Gupta, A., & Peighambari, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_185
Eldrieny, A. M., Hamed, M. T., Diab, S. E., Deghidy, A. M., & Elwakil, B. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26661-4.00006-5
Lateral flow assays for cancer biomarkers
Malode, S. J., & Shetti, N. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23883-3.00012-x
Wong, A. N. M., Callahan, J., Keyaerts, M., Neyns, B., Mangana, J., Aberle, S., Herschtal, A., Fullerton, S., Milne, D., Amir, I., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12307817
Mason, M., Lapuente-Santana, Ó., Halkola, A. S., Wang, W., Mall, R., Xiao, X., Kaufman, J. M., Fu, J., Pfeil, J., Banerjee, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26683642
Izevbaye, I. (2026) · Biomedicines · doi:10.3390/biomedicines14010175 · Cited by 3
Bridging cancer cell-intrinsic driver genes and -extrinsic cell-cell communication with Driver2Comm
Xie, R., Li, J., Hu, Y., & Gao, L. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013973
Vercellino, L. (2017) · theses.fr (ABES) · doi:10.70675/bd83d31bz69ecz46a1z92b1z8e459d3f81ee
Malissen, N. (2018) · theses.fr (ABES) · doi:10.70675/6e683c4ez28c0z442azaf6az7efb18488bc9
Control of antitumor immunity by the SQSTM1 dependent signaling
Yazbeck, N. (2018) · theses.fr (ABES) · doi:10.70675/3eee578bzb29fz4a95z8a1az99fa6d5edb80
Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725
Rôle de Programmed cell Death-Ligand 1 dans la progression du carcinome hépatocellulaire
Rousseau, B. (2021) · theses.fr (ABES) · doi:10.70675/dd181429zd664z4681zbe04z06271b5e1f39
Targeting the cell cycle : A novel therapeutic strategy against ATIP3- deficient breast cancer
Haykal, M. M. (2023) · theses.fr (ABES) · doi:10.70675/03dee32bz395cz469ez9a0dzf4c5f2e84330
Trachu, N., Anantaya, D., Iemwimangsa, N., Amponnavarat, S., Teoh, V.-H., Oranratnachai, S., Khiewngam, K., Thamrongjirapat, T., Monnamo, N., Lumjiaktase, P., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1787457
Immunotherapy and Breast Reconstruction: Opportunities, Challenges, and Future Directions
Li, S., Wang, J., Liu, Y., Cai, W., Zhang, W., Li, S., & Zhang, Y. (2026) · Cancer Medicine · doi:10.1002/cam4.71794
Chen, Q., Zhou, J., Zhao, B., & Xin, J. (2026) · European journal of medical research · doi:10.1186/s40001-026-04918-4
Wang, Y., Lei, X., de Wit, T., Schrama, E., Welters, M. J. P., van Leeuwen, K., de Kivit, S., de Boer, M., van den Bulk, J., de Miranda, N. F. C. C., et al. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101533
Introduction to personalized cellular immunotherapy
Reyed, R. M., Sah, A. K., Mohanty, S., & Prabhakar, P. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27731-3.00011-5
Zheng, C., Pan, Y., Zheng, D., & Pan, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1934879
Leutiger, J., Bathon, M., Möhring, C., Hubert, M. O., Leyh, C., Schlaak, A. E., Mitzlaff, K., Krämer, L., Neumann‐Haefelin, C., Zimpel, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1889205
Zhang, H., Zhang, N., Liang, X., Wen, J., Dai, Z., Wu, W., Li, S., Feng, S., Liu, Z., Xia, Z., et al. (2026) · Advanced Science · doi:10.1002/advs.76905
Zhao, X., Wang, H., Liu, Y., & Cao, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1919294
Schuiveling, M., Liu, H., Eek, D., Hanusová, M., van Duin, I. A. J., ter Maat, L. S., van der Weerd, J. C., van den Berkmortel, F. W. P. J., Blank, C. U., Breimer, G. E., et al. (2026) · Medical Image Analysis · doi:10.1016/j.media.2026.104334 · Cited by 1
Metadata
- Authors
- Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of California, Los Angeles (US)
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 658-660
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2346108121
- Cited by
- 748
- References
- 36
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 54 · 2023: 61 · 2022: 66 · 2021: 92 · 2020: 113 · 2019: 78 · 2018: 104 · 2017: 94 · 2016: 23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-immune interactions, tumor immune microenvironment, immune checkpoint inhibitors, precision oncology, immune profiling
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, T-Lymphocytes, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Mice, Precision Medicine, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.